Bevacizumab (1) – Lytenava®
Neovascular age-related macular degeneration
Characteristics
| Start date | 01.05.2025 – Marketing authorisation: 27.05.2024 |
|---|---|
| Resolution | 16.10.2025 |
| INN | Bevacizumab |
| Brand name | Lytenava® |
| Pharm. company | Outlook Therapeutics Limited |
| G-BA Procedure ID | D-1192 |
| ATC code | S01LA08 Antineovascularisation agents (S01LA) |
| ICD-10 codes (AIS) | H35.30Age-related macular degeneration |
| Alpha-ID codes (AIS) | I129318Age-related wet macular degeneration |
| Therapeutic area | Eye diseases |
| Reason for procedure | Initial assessment |
| Therapeutic indication of the resolution |
|---|
|
Lytenava is used in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD). |
| Subpopulation | Indication | Comparator |
|---|---|---|
| Erwachsene mit neovaskulärer (feuchter) altersbedingter Makuladegeneration (nAMD) |
Studies and Results
- Clinical trials
- Both studies were double-blind, randomised Phase III trials comparing bevacizumab with ranibizumab in patients aged 50 and over with neovascular age-related macular degeneration.
Adults with neovascular (wet) age-related macular degeneration (nAMD)
- The additional benefit is not proven.
- Overall, therefore, an additional benefit of bevacizumab over the appropriate comparator therapy has not been proven in adults with neovascular (wet) age-related macular degeneration.
- Overall assessment
- On balance, therefore, the additional benefit of bevacizumab over the appropriate comparator therapy is not proven in adults with neovascular (wet) age-related macular degeneration.
Courtesy translation only, please refer to the German original.
Associated procedures
| Bevacizumab (1) | Lytenava® | Outlook Therapeutics Limited | Neovascular age-related macular degeneration | 85,500–504,400 | 100% additional benefit not proven |
<< List of all resolutions